Assuntos
Bortezomib/efeitos adversos , Mieloma Múltiplo/tratamento farmacológico , Atrofia Óptica/induzido quimicamente , Disco Óptico/patologia , Antineoplásicos/efeitos adversos , Antineoplásicos/uso terapêutico , Bortezomib/uso terapêutico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Atrofia Óptica/diagnóstico , Tomografia de Coerência Óptica/métodos , Acuidade VisualRESUMO
Glial progenitor cells (GPCs) are a potential source of malignant gliomas. We used A2B5-based sorting to extract tumorigenic GPCs from human gliomas spanning World Health Organization grades II-IV. Messenger RNA profiling identified a cohort of genes that distinguished A2B5+ glioma tumor progenitor cells (TPCs) from A2B5+ GPCs isolated from normal white matter. A core set of genes and pathways was substantially dysregulated in A2B5+ TPCs, which included the transcription factor SIX1 and its principal cofactors, EYA1 and DACH2. Small hairpin RNAi silencing of SIX1 inhibited the expansion of glioma TPCs in vitro and in vivo, suggesting a critical and unrecognized role of the SIX1-EYA1-DACH2 system in glioma genesis or progression. By comparing the expression patterns of glioma TPCs with those of normal GPCs, we have identified a discrete set of pathways by which glial tumorigenesis may be better understood and more specifically targeted.
